Literature DB >> 9817285

Constitutional WT1 mutations in Wilms' tumor patients.

L Diller1, M Ghahremani, J Morgan, P Grundy, C Reeves, N Breslow, D Green, D Neuberg, J Pelletier, F P Li.   

Abstract

PURPOSE: Patients with Wilms' tumors (WT) who carry constitutional mutations in the WT1 gene have been described in case reports and small case series. We sought to determine the frequency of constitutional WT1 mutations in a larger cohort, and to identify clinical manifestations associated with the risk for carrying a WT1 mutation.
METHODS: We collected clinical data and blood samples from 201 patients with a history of WT. Southern blot analysis, single-strand conformation polymorphism (SSCP) analysis, and direct DNA sequencing were performed on DNA isolated from peripheral-blood lymphocytes from each patient. Odds ratios (ORs) for the carriage of a germline mutation of the WT1 gene were calculated for patients who had specific clinical risk factors compared with those who did not.
RESULTS: Of 201 patients with WT in the cohort, eight patients were carriers of mutations in the WT1 gene. Six of the eight mutations were protein-truncating nonsense mutations. None of 56 patients with isolated unilateral WT was a carrier. The OR of carrying a WT1 mutation was elevated for patients with genitourinary anomalies (OR19.3; P < .002). Seven of 28 boys with WT with cryptorchidism carried WT1 mutations. No increased risk was observed for patients with nephrogenic rests, bilateral tumors, history of secondary cancers, or family history of WT.
CONCLUSION: Germline WT1 mutations in patients with WT are associated with genitourinary anomalies, especially cryptorchidism and/or hypospadias. Patients with WT and no genitourinary anomalies are at low risk for carrying a WT1 mutation. Constitutional WT1 mutations that encode truncated WT1 proteins may predispose to the development of cryptorchidism, hypospadias, and WTs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817285     DOI: 10.1200/JCO.1998.16.11.3634

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  14 in total

1.  Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.

Authors:  Michael K Brawer; Stacy Loeb; Alan W Partin; Jayabalan Nirmal; Michael B Chancellor; J Curtis Nickel; Jacob Rajfer; Ellen Shapiro; Claus G Roehrborn
Journal:  Rev Urol       Date:  2011

2.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.

Authors:  Jane Lange; Susan M Peterson; Janice R Takashima; Yevgeny Grigoriev; Michael L Ritchey; Robert C Shamberger; J Bruce Beckwith; Elizabeth Perlman; Daniel M Green; Norman E Breslow
Journal:  J Urol       Date:  2011-06-17       Impact factor: 7.450

3.  Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1.

Authors:  D J Richard; V Schumacher; B Royer-Pokora; S G Roberts
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

4.  End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System.

Authors:  Norman E Breslow; Allan J Collins; Michael L Ritchey; Yevgeny A Grigoriev; Susan M Peterson; Daniel M Green
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

Review 5.  A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome.

Authors:  Suzanne Little; Sandra Hanks; Linda King-Underwood; Sue Picton; Catherine Cullinane; Elizabeth Rapley; Nazneen Rahman; Kathy Pritchard-Jones
Journal:  Pediatr Nephrol       Date:  2004-10-21       Impact factor: 3.714

Review 6.  WT1 and glomerular diseases.

Authors:  Patrick Niaudet; Marie-Claire Gubler
Journal:  Pediatr Nephrol       Date:  2006-08-23       Impact factor: 3.714

7.  Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor.

Authors:  Norman E Breslow; J Bruce Beckwith; Elizabeth J Perlman; Anthony E Reeve
Journal:  Pediatr Blood Cancer       Date:  2006-09       Impact factor: 3.167

Review 8.  Controversies and advances in the management of Wilms' tumour.

Authors:  K Pritchard-Jones
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

9.  A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation.

Authors:  Y Kaneko; H Okita; M Haruta; Y Arai; T Oue; Y Tanaka; H Horie; S Hinotsu; T Koshinaga; A Yoneda; Y Ohtsuka; T Taguchi; M Fukuzawa
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

Review 10.  Recent progress in the biology and treatment of Wilms' tumor.

Authors:  M L Ritchey
Journal:  Curr Urol Rep       Date:  2001-04       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.